ClinicalTrials.gg
CompletedNCT00191334Updated Mar 27, 2009Results posted

Gemcitabine in Ovarian Cancer

A Phase 2 interventional study of gemcitabine and cisplatin in Ovarian Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-27.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies testing gemcitabine in Ovarian Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Gemcitabine · Ovarian Neoplasms.

Enrollment
12th of 34
50 · median 39
Started
2004
with 1 other
Phase 2
21 of 40
none open now
Registered
17th of 40
by date
Lead sponsor
3 of 40
Eli Lilly and Company

Among the 40 studies testing gemcitabine in Ovarian Neoplasms, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2004, is one of 21 in phase 2, and was the 17th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 40 studies testing gemcitabine in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing gemcitabine in Ovarian Neoplasms as a file.
02

Study summary

The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • = 0-2
  • Operated patients
  • disease stage III-IV

Exclusion criteria

Exclusion Criteria:

  • No prior chemotherapy or radiation therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    A

    Drug: gemcitabine · Drug: cisplatin

Interventions

  • 1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity

    Also known as: LY188011, Gemzar

  • 75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity

06

What researchers measure

Primary outcomes

  1. Best Overall Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

    Time frame: every other 21 day cycle (6-8 cycles), every 3 months during long-term follow-up

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up

  2. Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

    Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up

  3. Time to Treatment Failure

    Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

    Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up

  4. Number of Patients With Maximum Common Toxicity Criteria - National Cancer Institute (CTC-NCI): Possibly Related to Study Drug by Grade

    Grades range from 0 (no toxicity) to 4 (life-threatening or disabling).

    Time frame: every 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up

07

Results

Posted Mar 27, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + Cisplatin
Started50
Completed33
Not completed17
Withdrew: Adverse event4
Withdrew: Disease progression or relapse8
Withdrew: Physician decision1
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryBest Overall Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

Time frame:
every other 21 day cycle (6-8 cycles), every 3 months during long-term follow-up
Reported as:
Number · participants
Best Overall Tumor Response
participantsGemcitabine + Cisplatin
Complete Response6
Partial Response25
Stable Disease10
Progressive Disease5
Not Assessed4
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Reported as:
Median · weeks
Duration of Response
weeksGemcitabine + Cisplatin
Duration of Response37.0 (31.1 to 51.1)
SecondaryTime to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

Time frame:
every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Reported as:
Median · weeks
Time to Progressive Disease
weeksGemcitabine + Cisplatin
Time to Progressive Disease45.1 (37.9 to 56.9)
SecondaryTime to Treatment Failure

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

Time frame:
every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Reported as:
Median · weeks
Time to Treatment Failure
weeksGemcitabine + Cisplatin
Time to Treatment Failure38.4 (29.1 to 48.3)
SecondaryNumber of Patients With Maximum Common Toxicity Criteria - National Cancer Institute (CTC-NCI): Possibly Related to Study Drug by Grade

Grades range from 0 (no toxicity) to 4 (life-threatening or disabling).

Time frame:
every 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Reported as:
Number · participants
Number of Patients With Maximum Common Toxicity Criteria - National Cancer Institute (CTC-NCI): Possibly Related to Study Drug by Grade
participantsGemcitabine + Cisplatin
Patients with at least one CTC - Grade 134
Patients with at least one CTC - Grade 26
Patients with at least one CTC - Grade 32
Patients with at least one CTC - Grade 41
Other auditory/hearing - Grade 10
Other auditory/hearing - Grade 20
Other auditory/hearing - Grade 31
Other auditory/hearing - Grade 40
Leukocytes - Grade 10
Leukocytes - Grade 20
Leukocytes - Grade 30
Leukocytes - Grade 41
Neutrophils/granulocytes - Grade 10
Neutrophils/granulocytes - Grade 20
Neutrophils/granulocytes - Grade 30
Neutrophils/granulocytes - Grade 41
Fatigue - Grade 111
Fatigue - Grade 20
Fatigue - Grade 31
Fatigue - Grade 40
Weight loss - Grade 10
Weight loss - Grade 21
Weight loss - Grade 30
Weight loss - Grade 40
Alopecia - Grade 11
Alopecia - Grade 21
Alopecia - Grade 30
Alopecia - Grade 40
Rash/desquamation - Grade 12
Rash/desquamation - Grade 20
Rash/desquamation - Grade 31
Rash/desquamation - Grade 40
Anorexia - Grade 11
Anorexia - Grade 20
Anorexia - Grade 30
Anorexia - Grade 40
Diarrhea (without colostomy) - Grade 10
Diarrhea (without colostomy) - Grade 20
Diarrhea (without colostomy) - Grade 31
Diarrhea (without colostomy) - Grade 40
Nausea - Grade 129
Nausea - Grade 22
Nausea - Grade 30
Nausea - Grade 40
Other Gastrointestinal - Grade 10
Other Gastrointestinal - Grade 21
Other Gastrointestinal - Grade 30
Other Gastrointestinal - Grade 40
Stomatitis/pharyngitis - Grade 10
Stomatitis/pharyngitis - Grade 20
Stomatitis/pharyngitis - Grade 31
Stomatitis/pharyngitis - Grade 40
Vomiting - Grade 124
Vomiting - Grade 20
Vomiting - Grade 30
Vomiting - Grade 40
Alkaline phosphatase - Grade 113
Alkaline phosphatase - Grade 21
Alkaline phosphatase - Grade 30
Alkaline phosphatase - Grade 40
Bilirubin - Grade 16
Bilirubin - Grade 20
Bilirubin - Grade 30
Bilirubin - Grade 40
Serum glutamic oxaloacetic transaminase - Grade 18
Serum glutamic oxaloacetic transaminase - Grade 20
Serum glutamic oxaloacetic transaminase - Grade 30
Serum glutamic oxaloacetic transaminase - Grade 40
Serum glutamic pyruvic transaminase - Grade 17
Serum glutamic pyruvic transaminase - Grade 20
Serum glutamic pyruvic transaminase - Grade 30
Serum glutamic pyruvic transaminase - Grade 40
Dizziness/lightheadedness - Grade 11
Dizziness/lightheadedness - Grade 20
Dizziness/lightheadedness - Grade 30
Dizziness/lightheadedness - Grade 40
Headache - Grade 10
Headache - Grade 21
Headache - Grade 30
Headache - Grade 40
Creatinine - Grade 17
Creatinine - Grade 21
Creatinine - Grade 30
Creatinine - Grade 40
Renal failure - Grade 10
Renal failure - Grade 20
Renal failure - Grade 31
Renal failure - Grade 40
Renal/genitourinary - Other - Grade 16
Renal/genitourinary - Other - Grade 22
Renal/genitourinary - Other - Grade 31
Renal/genitourinary - Other - Grade 40

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Cisplatin———
Most frequent serious events
Most frequent serious events
EventGemcitabine + Cisplatin
LeukopeniaBlood and lymphatic system disorders1/50
NeutropeniaBlood and lymphatic system disorders1/50
DeafnessEar and labyrinth disorders1/50
Renal failure acuteRenal and urinary disorders1/50
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGemcitabine + Cisplatin
NauseaGastrointestinal disorders32/50
VomitingGastrointestinal disorders25/50
AstheniaGeneral disorders17/50
Blood alkaline phosphatase increasedInvestigations15/50
Aspartate aminotransferase increasedInvestigations14/50
Weight decreasedInvestigations11/50
Blood creatinine increasedInvestigations10/50
Alanine aminotransferase increasedInvestigations9/50
Creatinine renal clearance decreasedInvestigations9/50
Weight increasedInvestigations9/50

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + Cisplatin
Mean54.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + Cisplatin
Female50
Male0
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + Cisplatin
Russian Federation50
Disease Stage
Disease Stage(participants)Gemcitabine + Cisplatin
Stage I - Tumor Limited to Ovaries0
Stage II - Pelvic Extension and/or Implants0
Stage IIIa - Microscopic Peritoneal Metastasis1
Stage IIIb - Macroscopic Peritoneal Metastasis3
Stage IIIc - Peritoneal Metastasis More Than 2 cm21
Stage IV - Distant Metastases25
Eastern Cooperative Oncology Group Performance Status Score
Eastern Cooperative Oncology Group Performance Status Score(participants)Gemcitabine + Cisplatin
0 - Fully Active28
1 - Ambulatory, Restricted Strenuous Activity20
2 - Ambulatory, No Work Activities2
3 - Partially Confined to Bed, Limited Self Care0
4 - Completely Disabled0
Postoperational Pathomorphological Diagnosis
Postoperational Pathomorphological Diagnosis(participants)Gemcitabine + Cisplatin
Serous Cystadenocarcinoma37
Mucinosa Cystadenocarcinoma3
Endometrioid Carcinoma4
Other6
Race/Ethnicity
Race/Ethnicity(participants)Gemcitabine + Cisplatin
Caucasian49
Other1
State of Patient Relative to Menopause
State of Patient Relative to Menopause(participants)Gemcitabine + Cisplatin
Fertile Period4
Post-Menopause46

1 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Irkutsk, Russian Federation
  • For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ivanovo, Russian Federation
  • For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, Russian Federation
  • For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Petersburg, Russian Federation
  • For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stavropol, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Dec 2004
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Mar 27, 2009
Last update
Mar 27, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191334
First posted
Sep 19, 2005
Start date
Dec 2004
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Mar 27, 2009
Last update
Mar 27, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion